Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

doi:10.1093/oncolo/oyaf362

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

The oncologist - 11 Nov 2025

Nguyen Matthew K, Jelinek Mark, Singh Arjun, Isett Brian, Myers Erica S, Mullett Steven J, Eisele Yvonne, Beumer Jan H, Parise Robert A, Urban Julie, Rose Amy, Sellitto Lorenzo, Singh Krishna, Doerfler Rose, Dadey Rebekah E, Kim Carl, Rhee John C, Davar Diwakar, Villaruz Liza C, Burgess Melissa, Drappatz Jan, Mantica Megan, Goodman Amy E, Wang Hong, Singhi Aatur D, Luke Jason J, Zandberg Dan P, Bao Riyue

Abstract excerpt

BACKGROUND: Cancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I/II interferon signaling and CD8+ T cell infiltration. We previously reported IDH1 somatic mutations were enriched in this phenotype across histologies. Mutant IDH1 (mIDH1) drives immune exclusion via metabolic reprogramming of the TME, and preclinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Neoplasms

Share to Nivolumab

Share to Pyridines

Share to Translational Research, Biomedical

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41138165
DOI: 10.1093/oncolo/oyaf362
PMCID: PMC12605714

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.PMID 41138165Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsSemantic proximity Read ↗

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.Semantic proximity Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Semantic proximity Read ↗

Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.Semantic proximity Read ↗

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

HMPL-306 (Ranosidenib): The Next Frontier in mIDH Cancer TherapySemantic proximity Read ↗

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1Semantic proximity Read ↗

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.